Clinical islet transplantation

Dixon B. Kaufman*, William L. Lowe

*Corresponding author for this work

Research output: Contribution to journalReview article

13 Citations (Scopus)

Abstract

Type 1 diabetes affects over 1 million persons in the United States, with over 30,000 new cases diagnosed annually. Transplantation of new insulin-producing β cells, in the form of the whole pancreas or isolated islets, has been shown to ameliorate the disease by eliminating the need for exogenous insulin and normalizing glycosylated hemoglobin levels. Islet transplants are a particularly attractive form of therapy because they are a minimally invasive procedure and are more likely to be scaled-up to treat the large numbers of people affected by diabetes. Currently, only a handful of programs have been successful in the endeavor. Nevertheless, the early clinical experience strongly demonstrates that islet transplantation is an effective treatment strategy in select patients with type 1 diabetes. To scale up this therapy and use it earlier in the disease and for more people, the shortage of suitable donor tissue must be solved and the requirement of lifelong immunosuppression must be minimized.

Original languageEnglish (US)
Pages (from-to)344-350
Number of pages7
JournalCurrent diabetes reports
Volume3
Issue number4
DOIs
StatePublished - Aug 2003

Fingerprint

Islets of Langerhans Transplantation
Type 1 Diabetes Mellitus
Insulin
Glycosylated Hemoglobin A
Immunosuppression
Pancreas
Therapeutics
Transplantation
Tissue Donors
Transplants

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Kaufman, Dixon B. ; Lowe, William L. / Clinical islet transplantation. In: Current diabetes reports. 2003 ; Vol. 3, No. 4. pp. 344-350.
@article{e9f01221dd6b468fb82fa3a9b471d8a3,
title = "Clinical islet transplantation",
abstract = "Type 1 diabetes affects over 1 million persons in the United States, with over 30,000 new cases diagnosed annually. Transplantation of new insulin-producing β cells, in the form of the whole pancreas or isolated islets, has been shown to ameliorate the disease by eliminating the need for exogenous insulin and normalizing glycosylated hemoglobin levels. Islet transplants are a particularly attractive form of therapy because they are a minimally invasive procedure and are more likely to be scaled-up to treat the large numbers of people affected by diabetes. Currently, only a handful of programs have been successful in the endeavor. Nevertheless, the early clinical experience strongly demonstrates that islet transplantation is an effective treatment strategy in select patients with type 1 diabetes. To scale up this therapy and use it earlier in the disease and for more people, the shortage of suitable donor tissue must be solved and the requirement of lifelong immunosuppression must be minimized.",
author = "Kaufman, {Dixon B.} and Lowe, {William L.}",
year = "2003",
month = "8",
doi = "10.1007/s11892-003-0028-7",
language = "English (US)",
volume = "3",
pages = "344--350",
journal = "Current Diabetes Reports",
issn = "1534-4827",
publisher = "Current Medicine Group",
number = "4",

}

Clinical islet transplantation. / Kaufman, Dixon B.; Lowe, William L.

In: Current diabetes reports, Vol. 3, No. 4, 08.2003, p. 344-350.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Clinical islet transplantation

AU - Kaufman, Dixon B.

AU - Lowe, William L.

PY - 2003/8

Y1 - 2003/8

N2 - Type 1 diabetes affects over 1 million persons in the United States, with over 30,000 new cases diagnosed annually. Transplantation of new insulin-producing β cells, in the form of the whole pancreas or isolated islets, has been shown to ameliorate the disease by eliminating the need for exogenous insulin and normalizing glycosylated hemoglobin levels. Islet transplants are a particularly attractive form of therapy because they are a minimally invasive procedure and are more likely to be scaled-up to treat the large numbers of people affected by diabetes. Currently, only a handful of programs have been successful in the endeavor. Nevertheless, the early clinical experience strongly demonstrates that islet transplantation is an effective treatment strategy in select patients with type 1 diabetes. To scale up this therapy and use it earlier in the disease and for more people, the shortage of suitable donor tissue must be solved and the requirement of lifelong immunosuppression must be minimized.

AB - Type 1 diabetes affects over 1 million persons in the United States, with over 30,000 new cases diagnosed annually. Transplantation of new insulin-producing β cells, in the form of the whole pancreas or isolated islets, has been shown to ameliorate the disease by eliminating the need for exogenous insulin and normalizing glycosylated hemoglobin levels. Islet transplants are a particularly attractive form of therapy because they are a minimally invasive procedure and are more likely to be scaled-up to treat the large numbers of people affected by diabetes. Currently, only a handful of programs have been successful in the endeavor. Nevertheless, the early clinical experience strongly demonstrates that islet transplantation is an effective treatment strategy in select patients with type 1 diabetes. To scale up this therapy and use it earlier in the disease and for more people, the shortage of suitable donor tissue must be solved and the requirement of lifelong immunosuppression must be minimized.

UR - http://www.scopus.com/inward/record.url?scp=0141560309&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141560309&partnerID=8YFLogxK

U2 - 10.1007/s11892-003-0028-7

DO - 10.1007/s11892-003-0028-7

M3 - Review article

C2 - 12866999

AN - SCOPUS:0141560309

VL - 3

SP - 344

EP - 350

JO - Current Diabetes Reports

JF - Current Diabetes Reports

SN - 1534-4827

IS - 4

ER -